# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.) \*

# **ZyVersa Therapeutics, Inc.**

(Name of Issuer)

#### Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

#### 98987D 102

(CUSIP Number)

#### **January 13, 2023**

(Date of Event which Requires Filing of this Statement)

[_] Rule 13d-1(b)					
[_] Rule 13d-1(c)					
[_] Rule 13d-1(d)					
 	 	_	_	 	 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

## **SCHEDULE 13G**

CUSIP No. 98987D 102

1 Names of Reporting Persons									
	Shawn M. Titcomb								
2	Check the appropriate box if a member of a Group (see instructions)								
	(a) [] (b) []								
3	Sec Use Only								
4	4 Citizenship or Place of Organization								
	United States								
		5	Sole Voting Power						
	Number of Shares Beneficially Owned by Each Reporting Person With:		874,698						
			Shared Voting Power						
			0						
			Sole Dispositive Power						
			874,698						
			Shared Dispositive Power						
			0						
9	Aggregate Amoun	t Benefi	cially Owned by Each Reporting Person						
	874,698	874,698							
10	Check box if the a	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)							
11	Percent of class re	Percent of class represented by amount in row (9)							
	9.63%								
12	Type of Reporting Person (See Instructions)								
	IN								

Item 1	l <b>.</b>							
(a)	Name of Issuer: ZyVersa Therapeutics, Inc.							
(b)	Address of Issuer's Principal Executive Offices: 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326							
Item 2	2.							
(a)	Name of Person Filing: Shawn M. Titcomb							
(b)	<b>Address of Principal Business Office or, if None, Residence:</b> 275 Commercial Blvd., Suite 333, Lauderdale by the Sea Florida 33308							
(c)	Citiz	enship:	United States					
(d)	Title and Class of Securities: Common stock, par value \$0.0001 per share							
(e)	CUS	IP No.:	98987D 102					
Item 3	3. I a:		eatement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is					
	(a)	[_]	Broker or dealer registered under Section 15 of the Act;					
	(b)		Bank as defined in Section 3(a)(6) of the Act;					
	(c)		Insurance company as defined in Section 3(a)(19) of the Act;					
	(d)		Investment company registered under Section 8 of the Investment Company Act of 1940;					
	(e)		An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);					
	(f)	[_]	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);					
	(g)		A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);					
	(h)		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);					
	(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;					
	(j)	[_]	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);					
	(k)		Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:					
Item 4	l. Own	ership						
(a)	Amo	ount Ber	neficially Owned: 874,698					

Page 3 of 5

- **(b) Percent of Class:** 9.63% based on 9,081,922 shares of Common Stock issued and outstanding as of January 13, 2023 based on information provided by the Issuer and other public information.
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: 874,698
  - (ii) Shared power to vote or to direct the vote: 0
  - (iii) Sole power to dispose or to direct the disposition of: 874,698
  - (iv) Shared power to dispose or to direct the disposition of: 0
- Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

- Item 6. Ownership of more than Five Percent on Behalf of Another Person. Not Applicable.
- Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. Not Applicable.
- Item 8. Identification and classification of members of the group. Not Applicable.
- Item 9. Notice of Dissolution of Group. Not Applicable.
- Item 10. Certifications.

## **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 13, 2023

/s/ Shawn M. Titcomb

Shawn M. Titcomb

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).